AdvanDx Raises $8 Million
AdvanDx, a provider of molecular diagnostic products for bacterial infections, has raised $8 million in new Series C funding. Return backers include SLS Venture and LD Pensions.
18 August 2009•3 mins read
AdvanDx, a provider of molecular diagnostic products for bacterial infections, has raised $8 million in new Series C funding. Return backers include SLS Venture and LD Pensions.
